Coin Metrics is the leading provider of crypto financial intelligence, offering network data, market data, indexes and network risk solutions to the most prestigious institutions touching cryptoassets. Coin Metrics was founded in 2017 as an open-source project to determine the economic significance of public blockchains. Today, they expand on that original purpose to empower people and institutions to make informed crypto financial decisions. Coin Metrics aim to usher the world’s premier financial institutions into crypto with the most trusted data and insights.
Coincover
Coincover provides a complete blockchain protection solution, addressing the most significant barrier to mainstream adoption: trust. Thier protection solutions ensure that access and assets are never lost. Today, Coincover helps over 350 of the biggest names in blockchain, including Fireblocks, BitGo, and Ledger, protect themselves and their customers from theft, hacking, and human error.
CLST
CLST (pronounced “Caeleste”) is the institutional communications venue to lend or borrow stablecoins and crypto assets, automating multi-dealer price negotiation and price matching for institutional lenders. CLST Markets integrates next generation features such as automated collateral management, counterparty risk assessments, interest rate benchmarking, blockchain-based electronic promissory notes and wallet connectivity for automated settlements. CLST aims to resolve market uncertainties and scaling issues in uncollateralized and collateralized lending and borrowing of stablecoins and crypto assets.
Casa
Casa is the secure home for your Bitcoin. The Company builds tools at the forefront of Bitcoin self-custody, enabling individuals to take control of their wealth by holding their own Bitcoin private keys in an easy and secure manner. Casa is building for a future where self-custody is default and every individual, family, and business can freely manage their own wealth and data.
Asymmetry Finance
Asymmetry Finance is an innovative synthetic dollar protocol, delivering a yield-bearing stablecoin that aims to be both inflation-resistant and scalable enough to meet the demands of an exponentially growing market.
Alluvial
Alluvial is a software development company supporting the development of the Liquid Collective protocol. Alluvial is focused on the overall growth and maturity of the ecosystem by fostering participation in proof of stake blockchains.
Amber Therapeutics
Amber Therapeutics is developing Amber-UI, a breakthrough adaptive neuromodulation therapy to treat women suffering with mixed urinary incontinence with the hope of transforming the clinical outcome and quality of life of a large untreated population. Amber-UI runs on the Company’s fully implantable Picostim system that targets the pudendal nerve to both stimulate and sense physiological responses. The therapy is configurable to the individual’s need and can respond dynamically to different events, adapting as needed between modes of operation. Amber’s technology platform is highly versatile and can be used to explore other novel therapy applications in both the pelvis and the broader nervous system, demonstrated by the work being carried out by the Company’s academic partnerships.
Xaira Therapeutics
Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intelligence to learn the language of life and transform how we treat disease. The company seeks to rethink the drug discovery and development process from end-to-end by bringing together leading talent across three core areas: machine learning research to better understand biology, expansive data generation to power new models, and robust therapeutic product development to treat disease.
Metsera
Metsera is a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases. Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and meet the future needs of a rapidly evolving weight loss treatment landscape.
nChromaBio
nChroma Bio is a pioneering biotechnology company redefining the future of in vivo targeted genetic medicine to treat a wide array of diseases and bring cures to patients. The company’s integrated product engine tackles significant limitations of existing genetic medicine approaches by enabling safe, precise and specific in vivo delivery. nChroma’s near clinical-stage development candidate, CRMA-1001, is a liver-targeted therapy in development as a potential functional cure for chronic hepatitis B and hepatitis D that leverages the power of epigenetics, nature’s innate mechanism for gene regulation. Guided by a world-class team at the forefront of genetic medicine, founded by renowned pioneers in the field, and supported by top-tier investors, the company is uniquely positioned to deliver groundbreaking therapies with programmable tissue specificity, unlocking highly potent, durable and targeted gene regulation for the liver and beyond.